Top Human Microbiome Companies

The global human microbiome market is projected to reach USD 7.09 billion by 2031 from USD 1.40 billion in 2025, at a CAGR of 31.0% during the forecast period.

Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US),  International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have implemented several strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to enhance their positions in the market. In 2025, Seres Therapeutics got approval for Rebyota in Canada, further expanding its geographical reach in North America. In December 2023, Ferring B.V. signed a licensing agreement with PharmaBiome to develop and commercialize defined-consortium microbiome therapeutics for gastroenterological conditions.

Seres Therapeutics (US): Seres Therapeutics is one of the emerging players in the human microbiome market. The company’s microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 64.6 million for the year ending December 31, 2024. It specializes in creating oral live biotherapeutic products with defined bacterial consortia intended to modulate the human microbiome. Its lead product, VOWST (formerly SER-109), received FDA approval in April 2023 to prevent recurrent Clostridioides difficile infection. VOWST is the first FDA-approved orally administered microbiome therapeutic. In 2023, Seres Therapeutics implemented organizational changes, including workforce reductions and a narrowed R&D focus. In June 2024, the company entered into an agreement with Nestlé Health Science to transfer full commercialization rights for VOWST. The company continues to pursue clinical development of its remaining programs and maintains collaborations with academic and industry partners.

FERRING B.V. (SWITZERLAND): Ferring Pharmaceuticals is a biopharmaceutical company involved in the development of microbiome-based therapeutics. The company operates in multiple therapeutic areas, including reproductive medicine, maternal health, gastroenterology, and urology. Ferring engages in internal research and external partnerships in the microbiome space. It acquired Rebiotix, a company developing live biotherapeutic products targeting human microbiome. The company developed Rebyota, a fecal microbiota-based therapeutic indicated for preventing recurrent Clostridioides difficile infection. The product received FDA approval in November 2022 and is administered via enema. It has also collaborated with organizations such as Karolinska Institutet, Intralytix, MyBiotics, and PharmaBiome to explore live microbial consortia, bacteriophage-based therapies, and microbiome diagnostics. The company maintains manufacturing and R&D operations in various regions and continues to advance its microbiome programs across therapeutic categories through preclinical and clinical development stages.

International Flavors & Fragrances Inc. (US): International Flavors & Fragrances (IFF) operates in the fields of flavor, fragrance, nutrition, and biosciences, with a growing focus on microbiome-based ingredients. The company has developed capabilities in precision fermentation and microbial strain engineering, enabling the industrial-scale production of next-generation probiotics, including strict anaerobes like Akkermansia. These technologies support ingredient development for applications in human and pet health, food, and supplements. IFF’s HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets like Brazil for reducing eczema risk in infants and pregnant women. IFF offers products such as HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets such as Brazil for reducing eczema risk in infants and pregnant women. IFF offers products like HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The microbiome innovation of IFF is supported by ongoing collaborations and a broader portfolio in synthetic biology, enabling the development of functional ingredients across consumer and health product categories.

Market Ranking

The human microbiome market is moderately consolidated, with key companies holding 60-67% of the global market share. These include Seres Therapeutics (US), Ferring Pharmaceuticals (Switzerland), International Flavors & Fragrances (IFF, US), Pedulum (Sweden), and Seed Health (US). Seres Therapeutics has established a strong position through the development and FDA approval of VOWST, a live biotherapeutic for recurrent Clostridioides difficile infection. Ferring Pharmaceuticals has expanded its presence via Rebiotix, and its product Rebyota has also been approved for C. difficile prevention. IFF contributes through its HOWARU portfolio of clinically studied probiotic strains used in dietary supplements and functional foods, supporting a broad range of health applications. Pendulum focuses on pediatric and adult gut health through evidence-backed probiotic formulations, distributed across global markets. Seed Health combines microbiome science with direct-to-consumer strategies, offering targeted probiotic and synbiotic products for digestive, skin, and systemic health.

These companies are driving innovation through clinical research, strategic partnerships, and investment in new delivery formats. Emerging markets in the Asia Pacific and Latin America present additional opportunities for expansion. Other players, including smaller firms and startups, hold the remaining 20-30% market share and contribute to product diversity and scientific advancement, although their influence is limited compared to the leading companies.

Related Reports:

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com